Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
Media Resources
2015
2014 Annual Report and Financial Statements
EU Clinical Trials Regulation: EMA Steers Away from Transparency by Misinterpreting Exception Provisions
2014
Retention of Medicines Policy in DG Health a Victory for Public Health Advocates
EMA’s Final Policy on Access to Clinical Data: Proactive Access to Some Data, But Strings Attached
EU Pharmacovigilance Public Hearings Should Be As Transparent and Independent as in US
Trading Away Access to Medicines – Revisited
Europe Seeks to Expand Big Pharma Monopoly at Expense of Poor People, Warn NGOs Ahead of TTIP Talks (2014)
Public Health in Danger with Move of Pharmaceutical Policy to DG Enterprise and Industry
Mapping External Reference Pricing Practices for Medicines
Investor-State Dispute Settlement in EU-US Trade Deal Risks Access to Affordable Medicines
EMA’s New Policy on Access to Clinical Data – About to Privatise Pharmaceutical Knowledge?
Health Action International Welcomes Adoption of New Clinical Trials Regulation by European Parliament
Health Action International Applauds Medicines Patent Pool, ViiV Healthcare Licensing Agreement for New HIV Treatment
The EU-US Trade Agreement – Proposals by Pharmaceutical Industry Undermine European Public Policymaking and Public Health
EU Regulation on Clinical Trials – Close to the Finish Line
2013 Annual Report and Financial Statements
2013 Annual Report and Financial Statements
Working Paper 4 – Competition Policy
Policy Brief 3 – Regulation of Mark-ups in the Pharmaceutical Supply Chain
Policy Brief 5 – Sales Taxes on Medicines
Policy Brief 2 – The Role of Health Insurance in the Cost-effective Use of Medicines
Working Paper 1 – External Reference Pricing
Policy Brief 4 – Competition Policy
Policy Brief 1 – External Reference Pricing
Working Paper 2 – The Role of Health Insurance in the Cost-Effective Use of Medicines
Working Paper 3: The Regulation of Mark-ups in the Pharmaceutical Supply Chain
Understanding and Responding To Medicines Promotion
2013